Brokers Offer Predictions for PHIO FY2024 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – HC Wainwright issued their FY2024 earnings estimates for shares of Phio Pharmaceuticals in a research report issued on Wednesday, February 19th. HC Wainwright analyst V. Bernardino expects that the company will earn ($8.54) per share for the year. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2024 earnings at ($1.23) EPS and FY2025 earnings at $3.76 EPS.

Phio Pharmaceuticals Price Performance

NASDAQ:PHIO opened at $1.67 on Friday. Phio Pharmaceuticals has a one year low of $1.53 and a one year high of $10.35. The firm’s 50 day simple moving average is $2.24 and its 200 day simple moving average is $2.67. The company has a market cap of $11.51 million, a PE ratio of -0.15 and a beta of 1.53.

Hedge Funds Weigh In On Phio Pharmaceuticals

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned about 0.59% of Phio Pharmaceuticals at the end of the most recent quarter. 57.31% of the stock is currently owned by institutional investors and hedge funds.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.